详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: A prospective, multicentre, non-interventional study(Open Access)

3| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Jiangsu Cancer Hospital, Nanjing 210000, China [2]Henan Cancer Hospital, Zhengzhou, China [3]Shanxi Cancer Hospital, Taiyuan, China [4]Shanghai Roche Pharmaceuticals Ltd, Shanghai, China [5]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [6]Jilin University First Affiliated Hospital, Changchun, China [7]Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China [8]The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China [9]Fourth Hospital of Hebei Medical University, Shijiazhuang, China [10]Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, China [11]Nanfang Medical University Nanfang Hospital, Guangzhou, China [12]Guangdong Foshan First Hospital, Foshan, China [13]Guangdong Zhongshan People’s Hospital, Zhongshan, China [14]Xiangya Hospital Central South University, Changsha, China [15]Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China [16]Changzhou First People’s Hospital, Changzhou, China [17]307 Hospital of PLA, Beijing, China [18]First Affiliated Hospital of Kunming Medical University, Kunming, China [19]Affiliated hospital of Neimenggu Medical College, Huhehaote, China [20]The Fourth Military Medical University Affiliated Tangdu Hospital, Xi’an, China [21]Daqing General Hospital Group Oilfield General Hospital, Daqing, China [22]Affiliated Hospital of Guiyang Medical College, Guiyang, China [23]Anhui Provincial Hospital, Hefei, China [24]Lanzhou Military Hospital, Lanzhou, China [25]Fujian provincial hospital, Fuzhou, China

出处：

DOI：

ISSN：

关键词： Chemotherapy DLBCL HBsAg HBV infection R-CHOP

摘要：

Background: The efficacy and safety of rituximab-based chemotherapy (R-chemo), the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL), which is more common in Asia than in Western countries, are well confirmed in randomized controlled trials (RCTs). However, the safety and effectiveness of R-chemo in patients who are largely excluded from RCTs have not been well characterized. This real-world study investigated the safety and effectiveness of R-chemo as first-line treatment in Chinese patients with DLBCL. Methods: Treatment-naive DLBCL patients who were CD20 positive and eligible to receive R-chemo were enrolled with no specific exclusion criteria. Data collected at baseline included age, gender, disease stage, international prognostic index (IPI), B symptoms, extranodal involvement, performance status, and medical history. In the present study, data on safety, treatment effectiveness, and HBV infection management were collected 120 days after the last R-chemo administration. Results: Overall, R-chemo was well tolerated. The safety profile of R-chemo in patients with a history of heart or liver disease was well described without any additional unexpected safety concerns. The overall response rate (ORR) in the Chinese patients from this study was 94.2 % (complete response [CR], 55.0 %; CR unconfirmed [CRu] 18.2 %; and partial response [PR], 20.9 %). Compared to patients with no history of disease, the CR and PR rates of patients with a history of heart or liver disease were lower and higher, respectively; this tendency could be in part explained by treatment interruptions in patients with heart or liver diseases. HBsAg positivity and a maximum tumor diameter of ≥7.5 cm negatively correlated with CR + CRu, whereas age and HBsAg positivity negatively correlated with CR. Conclusions: This study further validated the safety and effectiveness of R-chemo in Chinese patients with DLBCL. Patients with a history of heart or liver disease may further benefit from R-chemo if preventive measures are taken to reduce hepatic and cardiovascular toxicity. In addition to IPI and tumor diameter, HBsAg positivity could also be a poor prognostic factor for CR in Chinese patients with DLBCL. Trial registration: ClinicalTrials.gov # NCT01340443 , April 20, 2011. © 2016 Wu et al.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2016]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.4 最新[2023版] 3.8 最新五年平均 3.288 出版当年[2016版] 3.645 出版当年五年平均 3.265 出版前一年[2015版] 3.288 出版后一年[2017版]

第一作者：

第一作者机构： [1]Jiangsu Cancer Hospital, Nanjing 210000, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: A prospective, multicentre, non-interventional study(Open Access)

文献详情

相关文献